GABA (γ-aminobutyric acid) is the major inhibitory neurotransmitter in the CNS, and glutamate is the major excitatory neurotransmitter. Together they regulate nearly every brain function, and their pharmacology underlies the majority of antiseizure medications, sedative-hypnotics, anesthetics, NMDA antagonists used in neurology, alcohol/sedative withdrawal management, and emerging therapies for treatment-resistant depression and stroke neuroprotection. This page covers GABAergic and glutamatergic receptor systems, the drugs that act on them, and the neurological conditions they treat.

GABA System

Synthesis and Metabolism

  • Glutamate → GABA via glutamic acid decarboxylase (GAD); requires vitamin B6 (pyridoxal phosphate as cofactor).
  • Storage: vesicles.
  • Reuptake: GAT transporters (mainly GAT-1).
  • Metabolism: GABA transaminase (GABA-T) → succinic semialdehyde → succinate.

GABA Receptors

  • GABA-A: ligand-gated Cl⁻ channel; fast inhibition; pentameric (varied subunits: α, β, γ); allosteric modulation sites for benzodiazepines, barbiturates, alcohol, anesthetics, neurosteroids.
  • GABA-B: G-protein coupled; slow inhibition; pre- and postsynaptic; target of baclofen.
  • GABA-C: ligand-gated Cl⁻ channel; retina; minor clinical role.

GABA-A Subunit Composition and Pharmacology

  • α1: classical benzodiazepine site; sedative effects.
  • α2/α3: anxiolytic effects.
  • α5: cognitive effects (hippocampal).
  • δ-containing: extrasynaptic; tonic inhibition; alcohol; neurosteroids.

GABAergic Drugs

Benzodiazepines

  • Mechanism: positive allosteric modulators at GABA-A; increase frequency of Cl⁻ channel opening; require endogenous GABA.
  • Short-acting: midazolam, alprazolam, oxazepam.
  • Intermediate: lorazepam (preferred in liver disease — glucuronidation, not CYP), temazepam.
  • Long-acting: diazepam, clonazepam, chlordiazepoxide.
  • Uses: status epilepticus (lorazepam, diazepam, midazolam), alcohol withdrawal, anxiety, sleep, sedation, muscle relaxation, restless legs (clonazepam).
  • Side effects: sedation, ataxia, dependence, tolerance, withdrawal (seizures), cognitive effects, respiratory depression (with opioids).
  • Reversal: flumazenil (caution in chronic users — withdrawal seizures).
  • BEERS criteria — generally avoid in elderly.

Z-Drugs (Non-benzodiazepine Sedatives)

  • Zolpidem, zaleplon, eszopiclone: bind α1-subunit GABA-A; relatively selective sedation.
  • Insomnia treatment.
  • Less daytime carryover than benzos.
  • Still dependence/tolerance risk.
  • “Sleep behaviors” (driving, eating, sex without memory) — black box warning.

Barbiturates

  • Mechanism: GABA-A positive allosteric modulator; increase duration of Cl⁻ channel opening; at high doses can directly activate channel without GABA (lethal in overdose).
  • Phenobarbital: ASM; status epilepticus; CNS depression in opioid use disorder.
  • Pentobarbital, thiopental: refractory status epilepticus; coma induction.
  • Side effects: sedation, respiratory depression, enzyme induction, cognitive effects, dependence.
  • Largely supplanted by benzos and newer ASMs.

Baclofen (GABA-B Agonist)

  • Spasticity treatment.
  • Oral, intrathecal (programmable pump for severe spasticity in SCI, MS, cerebral palsy).
  • Withdrawal can be life-threatening (high fever, rebound spasticity, seizures, hallucinations) — intrathecal pump failure is emergency.
  • Side effects: sedation, weakness, hypotonia in overdose.

ASM with GABAergic Action

  • Tiagabine: GABA reuptake inhibitor (GAT-1); ASM (focal); risk of non-epileptic stupor.
  • Vigabatrin: GABA transaminase inhibitor; infantile spasms, refractory focal seizures; visual field defects → restricted use, monitoring.
  • Topiramate, valproate, levetiracetam: have GABAergic components among other mechanisms.

Anesthetics

  • Propofol: GABA-A positive modulator; rapid onset; ICU sedation; refractory status epilepticus.
  • Etomidate: GABA-A; minimal cardiovascular effect; concern about adrenal suppression with prolonged use.
  • Ketamine: NMDA antagonist (see glutamate).
  • Dexmedetomidine: α2 agonist; not GABAergic but produces sedation; covered in adrenergic.

Neurosteroids

  • Allopregnanolone, ganaxolone: positive allosteric modulators at GABA-A (especially δ-subunit extrasynaptic).
  • Ganaxolone FDA-approved for CDKL5 deficiency disorder.
  • Brexanolone (IV allopregnanolone): postpartum depression.
  • Zuranolone (oral allopregnanolone analog): postpartum depression.

Glutamate System

Synthesis and Metabolism

  • From α-ketoglutarate (Krebs cycle) and glutamine.
  • Storage: vesicles.
  • Reuptake: EAATs (astrocyte and neuronal); converted to glutamine by glutamine synthetase.

Glutamate Receptors

Ionotropic

  • AMPA: rapid Na⁺/K⁺ flux; fast excitatory transmission; target of perampanel (AMPA antagonist).
  • Kainate: similar to AMPA; less common.
  • NMDA: Ca²⁺-permeable; requires glutamate + glycine + voltage (Mg²⁺ block); central to LTP, learning; excitotoxicity in stroke; target of memantine, ketamine, esketamine, MK-801.

Metabotropic (mGluR)

  • Eight subtypes (mGluR1-8), three groups.
  • Group I (mGluR1, mGluR5): postsynaptic, excitatory.
  • Group II (mGluR2, mGluR3) and Group III (mGluR4, 6, 7, 8): presynaptic autoreceptors, inhibitory.
  • Therapeutic targeting limited; investigational.

Glutamatergic Drugs

NMDA Antagonists

  • Memantine: low-affinity, uncompetitive NMDA antagonist; for moderate-severe AD; protects against excitotoxicity; well-tolerated.
  • Amantadine: NMDA antagonist + dopamine release; PD dyskinesias.
  • Ketamine, esketamine (intranasal): rapid antidepressant; treatment-resistant depression; chronic pain; status epilepticus refractory.
  • Magnesium: Mg²⁺ blocks NMDA channel; therapeutic in eclampsia; investigational neuroprotection.
  • Dextromethorphan: NMDA antagonist + SERT/NET; combination dextromethorphan/quinidine for pseudobulbar affect (Nuedexta); combination dextromethorphan/bupropion (Auvelity) for depression.

AMPA Antagonists

  • Perampanel: selective non-competitive AMPA antagonist; ASM for focal and primary generalized tonic-clonic; black box for behavioral effects.

Other Glutamate Modulators

  • Riluzole: ALS treatment; multiple effects including glutamate modulation; modest survival benefit (2-3 months).
  • Topiramate, lamotrigine: among multiple mechanisms, include glutamate modulation.
  • Felbamate: NMDA antagonist (among other actions); ASM; restricted due to aplastic anemia.

Excitotoxicity

  • Excessive glutamate (e.g., in stroke ischemic core/penumbra) → massive NMDA activation → Ca²⁺ influx → neuronal death.
  • Therapeutic potential for NMDA modulation in stroke, TBI, neurodegeneration — clinically NOT yet established.
  • Memantine’s success in AD suggests modest, persistent NMDA modulation tolerable.

Clinical Applications

Status Epilepticus

  • Lorazepam (or diazepam, midazolam): first-line.
  • If refractory: phenytoin/fosphenytoin, valproate, levetiracetam (second-line).
  • Refractory: propofol, midazolam infusion, ketamine (NMDA antagonist), pentobarbital.

Alcohol/Sedative Withdrawal

  • Benzodiazepines first-line (lorazepam, diazepam).
  • Phenobarbital alternative.
  • Carbamazepine for milder withdrawal.

Spasticity

  • Oral baclofen, tizanidine, dantrolene.
  • Intrathecal baclofen for severe.
  • Botulinum toxin for focal.

Alzheimer Disease

  • Memantine moderate-severe; AChE inhibitors mild-moderate.
  • Combination memantine + donepezil shown beneficial.

Treatment-Resistant Depression

  • Esketamine (intranasal): FDA-approved.
  • Ketamine (IV): off-label, increasingly used.
  • Dextromethorphan/bupropion: Auvelity FDA-approved.
  • Brexanolone, zuranolone (postpartum depression).

Pseudobulbar Affect

  • Dextromethorphan/quinidine (Nuedexta).

ALS

  • Riluzole: modest survival benefit.
  • Edaravone: oxidative-stress modulator.
  • Tofersen (SOD1-targeting ASO): for SOD1-ALS.

Anti-NMDA Receptor Encephalitis

  • Autoimmune; antibodies against NMDA receptor.
  • Often paraneoplastic (ovarian teratoma).
  • Treatment: immunotherapy (steroids, IVIG, plasmapheresis, rituximab, cyclophosphamide).

🔍 Did You Know?

The rapid antidepressant effect of ketamine and esketamine represents one of the most exciting paradigm shifts in psychiatry and neurology in decades — and it works through glutamatergic mechanisms, not the monoaminergic pathways that have dominated antidepressant pharmacology since the 1950s. A single subanesthetic dose of ketamine can produce significant improvement in treatment-resistant depression within hours, with effects sometimes lasting weeks. The mechanism is incompletely understood but likely involves rapid synaptogenesis and dendritic spine formation driven by transient NMDA antagonism, increased AMPA receptor signaling, BDNF release, and modulation of inflammatory pathways. This is fundamentally different from SSRIs that take weeks to act through receptor downregulation. The clinical impact has been profound: esketamine (Spravato) is FDA-approved for treatment-resistant depression, IV ketamine is increasingly used in academic medical centers, and the dextromethorphan/bupropion combination (Auvelity) leverages similar glutamatergic mechanisms with oral administration. For the neurologist, this opens up: a new pharmacology of mood (especially relevant in stroke, PD, MS depression); a novel approach to acute suicidality (rapid effect is critical when patients are at risk); status epilepticus refractory option (ketamine in third-line); pain management innovation. The lesson generalizes: after decades of dominance, monoamine theory of depression is being augmented by glutamatergic and inflammatory theories, and the next generation of neuropsychiatric drugs increasingly target these systems.

Pitfalls and Pearls

  • GABA-A: fast inhibition; Cl⁻ channel; allosteric sites for benzodiazepines, barbiturates, alcohol, neurosteroids.
  • GABA-B: slow inhibition; baclofen target.
  • Benzodiazepines: first-line for status epilepticus, alcohol withdrawal, anxiety; tolerance/dependence.
  • Flumazenil: benzo reversal; caution in chronic users (withdrawal seizures).
  • Z-drugs: insomnia; less daytime carryover; still dependence risk; “sleep behaviors.”
  • Phenobarbital: ASM, status epilepticus, enzyme inducer.
  • Baclofen: spasticity; intrathecal for severe; withdrawal life-threatening.
  • NMDA: Ca²⁺-permeable; LTP, learning; excitotoxicity in stroke.
  • Memantine: low-affinity NMDA antagonist; moderate-severe AD.
  • Amantadine: NMDA antagonist + DA release; PD dyskinesias.
  • Ketamine, esketamine: rapid antidepressant; treatment-resistant depression; status epilepticus refractory.
  • Perampanel: AMPA antagonist; ASM; behavioral effects.
  • Riluzole: ALS; modest survival benefit.
  • Anti-NMDA receptor encephalitis: ovarian teratoma association; immunotherapy.
  • Vigabatrin: GABA transaminase inhibitor; infantile spasms; visual field defects.
  • Magnesium: NMDA channel block; eclampsia therapy.

References

  1. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.
  2. Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012;287(48):40224-40231.
  3. Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009;157(8):1301-1317.
  4. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.
  5. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Curr. 2016;16(1):48-61.
  6. Lipton SA. Failures and successes of NMDA receptor antagonists. Nat Rev Drug Discov. 2006;5(2):160-170.